Acquired mechanisms of immune escape in cancer following immunotherapy

Immunotherapy has revolutionized the management of numerous cancers; however, a substantial proportion that initially respond subsequently acquire means of immune escape and relapse. Analysis of recent clinical trials permits us to preliminarily understand how immunotherapies exert evolutionary pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryan Iorgulescu, J., Braun, David, Oliveira, Giacomo, Keskin, Derin B., Wu, Catherine J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249768/
https://www.ncbi.nlm.nih.gov/pubmed/30466478
http://dx.doi.org/10.1186/s13073-018-0598-2
_version_ 1783372813858504704
author Bryan Iorgulescu, J.
Braun, David
Oliveira, Giacomo
Keskin, Derin B.
Wu, Catherine J.
author_facet Bryan Iorgulescu, J.
Braun, David
Oliveira, Giacomo
Keskin, Derin B.
Wu, Catherine J.
author_sort Bryan Iorgulescu, J.
collection PubMed
description Immunotherapy has revolutionized the management of numerous cancers; however, a substantial proportion that initially respond subsequently acquire means of immune escape and relapse. Analysis of recent clinical trials permits us to preliminarily understand how immunotherapies exert evolutionary pressures: selecting cancer subclones deficient in antigenicity and/or immunogenicity, thereby facilitating immune escape.
format Online
Article
Text
id pubmed-6249768
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62497682018-11-26 Acquired mechanisms of immune escape in cancer following immunotherapy Bryan Iorgulescu, J. Braun, David Oliveira, Giacomo Keskin, Derin B. Wu, Catherine J. Genome Med Comment Immunotherapy has revolutionized the management of numerous cancers; however, a substantial proportion that initially respond subsequently acquire means of immune escape and relapse. Analysis of recent clinical trials permits us to preliminarily understand how immunotherapies exert evolutionary pressures: selecting cancer subclones deficient in antigenicity and/or immunogenicity, thereby facilitating immune escape. BioMed Central 2018-11-22 /pmc/articles/PMC6249768/ /pubmed/30466478 http://dx.doi.org/10.1186/s13073-018-0598-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Comment
Bryan Iorgulescu, J.
Braun, David
Oliveira, Giacomo
Keskin, Derin B.
Wu, Catherine J.
Acquired mechanisms of immune escape in cancer following immunotherapy
title Acquired mechanisms of immune escape in cancer following immunotherapy
title_full Acquired mechanisms of immune escape in cancer following immunotherapy
title_fullStr Acquired mechanisms of immune escape in cancer following immunotherapy
title_full_unstemmed Acquired mechanisms of immune escape in cancer following immunotherapy
title_short Acquired mechanisms of immune escape in cancer following immunotherapy
title_sort acquired mechanisms of immune escape in cancer following immunotherapy
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249768/
https://www.ncbi.nlm.nih.gov/pubmed/30466478
http://dx.doi.org/10.1186/s13073-018-0598-2
work_keys_str_mv AT bryaniorgulescuj acquiredmechanismsofimmuneescapeincancerfollowingimmunotherapy
AT braundavid acquiredmechanismsofimmuneescapeincancerfollowingimmunotherapy
AT oliveiragiacomo acquiredmechanismsofimmuneescapeincancerfollowingimmunotherapy
AT keskinderinb acquiredmechanismsofimmuneescapeincancerfollowingimmunotherapy
AT wucatherinej acquiredmechanismsofimmuneescapeincancerfollowingimmunotherapy

Ejemplares similares